Rapid Phenotypic Reversion of Zidovudine-resistant Feline Immunodeficiency Virus Without Loss of Drug-resistant Reverse Transcriptase
Overview
Authors
Affiliations
We have selected and plaque purified zidovudine (3'-azido-3'-deoxythymidine [AZT])-resistant mutants from an infectious molecular clone of feline immunodeficiency virus (FIV). The patterns of cross-resistance and drug susceptibilities of these mutants were similar to those of the AZT-resistant FIV that we previously selected in vitro from a wild-type FIV population and to those of the most common AZT-resistant clinical isolates of human immunodeficiency virus type 1. Two AZT-resistant mutants of FIV, one selected from a normal population and one selected from the molecular clone, each reverted rapidly to an AZT-sensitive phenotype when passaged in the absence of drug. Sequence analysis of the reverse transcriptase (RT)-encoding region from the plaque-purified AZT-resistant FIV revealed a single base change at position 2939, resulting in a Glu-to-Lys substitution at amino acid 202 of the RT. Similar analyses of plaque-purified revertants showed that the phenotypic reversion was not the result of a genotypic reversion at this position and that no additional mutations existed within the RT-encoding region of the revertants. Moreover, RTs purified from the mutant and revertant were both resistant to the 5'-triphosphate of AZT. These results indicate the complexity of AZT resistance and suggest the presence of additional factors, outside the RT-encoding region, which may contribute to AZT resistance.
Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus.
Hartmann K, Wooding A, Bergmann M Vet Sci. 2017; 2(4):456-476.
PMID: 29061953 PMC: 5644647. DOI: 10.3390/vetsci2040456.
Hartmann K J Feline Med Surg. 2015; 17(11):925-39.
PMID: 26486979 PMC: 10816252. DOI: 10.1177/1098612X15610676.
Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins.
Saenz D, Teo W, Olsen J, Poeschla E J Virol. 2005; 79(24):15175-88.
PMID: 16306589 PMC: 1316021. DOI: 10.1128/JVI.79.24.15175-15188.2005.
Smith R, Klarmann G, Stray K, von Schwedler U, Schinazi R, Preston B Antimicrob Agents Chemother. 1999; 43(8):2077-80.
PMID: 10428942 PMC: 89420. DOI: 10.1128/AAC.43.8.2077.
Smith R, Remington K, Preston B, Schinazi R, North T J Virol. 1998; 72(3):2335-40.
PMID: 9499094 PMC: 109533. DOI: 10.1128/JVI.72.3.2335-2340.1998.